Enhertu (trastuzumab deruxtecan)

pCPA File Number: 22045
Negotiation Status:
Under consideration for negotiation
Indication(s):
For the treatment of adult patients with unresectable or metastatic human epidermal growth factor receptor 2 (HER2)-positive breast cancer who have received a prior treatment with an anti-HER2-based regimen in the metastatic setting or developed disease recurrence during or within 6 months of completing neoadjuvant or adjuvant therapy
Sponsor/Manufacturer:
AstraZeneca Canada Inc.
CADTH Project Number:
PC0285
pCPA Engagement Letter Issued:
Not Applicable
Negotiation Process Concluded:
Not Applicable